Get the Stockscreener App
0.9605
1.44%
0.0136
After Hours:
.96
-0.0005
-0.05%
NanoViricides Inc stock is traded at $0.9605, with a volume of 171.70K.
It is up +1.44% in the last 24 hours and down -3.95% over the past month.
NanoViricides, Inc., a nano-biopharmaceutical company, discovers, develops, and commercializes therapeutics for the treatment of viral infections. The company is developing anti-influenza drug candidates at pre-clinical and advanced pre-clinical stage, which include two FluCide drugs, such as NV-INF-2, an oral anti-influenza drug and NV-INF-1, an injectable anti-influenza drug for H7N9, Bird Flu H5N1, and other Highly Pathogenic Influenzas; and HIVCide, an anti-human immunodeficiency virus (HIV) drug candidate that could provide functional cure for HIV/AIDS. It is also developing HerpeCide, a skin cream or gel formulation for the treatment of oral and genital herpes virus infections; and eye drops against viral infections of the external eye, as well as involved in the other research programs against Rabies virus, Ebola, and Marburg viruses. NanoViricides, Inc. was founded in 2005 and is based in Shelton, Connecticut.
See More
Previous Close:
$0.9469
Open:
$0.94
24h Volume:
171.70K
Relative Volume:
0.64
Market Cap:
$20.74M
Revenue:
-
Net Income/Loss:
$-8.32M
P/E Ratio:
-1.9944
EPS:
-0.4816
Net Cash Flow:
$-7.43M
1W Performance:
-8.52%
1M Performance:
-3.95%
6M Performance:
-32.36%
1Y Performance:
-24.37%
1-Day Range:
$0.9201
$0.9825
1-Week Range:
$0.9201
$1.0699
52-Week Range:
$0.85
$2.2299
NanoViricides Inc Stock (NNVC) Company Profile
Name
NanoViricides Inc
Sector
Industry
Phone
203-937-6137
Address
1 Controls Drive, Shelton, CT
Compare NNVC vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NNVC
NanoViricides Inc
|
0.9605 | 20.45M | 0 | -8.32M | -7.43M | -0.4816 |
VRTX
Vertex Pharmaceuticals Inc
|
453.74 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
756.73 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.16 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
692.83 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
147.60 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
NanoViricides Inc Stock (NNVC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-16-25 | Initiated | Alliance Global Partners | Buy |
| Feb-11-15 | Initiated | Midtown Partners | Strong Buy |
NanoViricides Inc Stock (NNVC) Latest News
Aug Retail: Can NanoViricides Inc generate free cash flowEarnings Beat & Real-Time Volume Analysis - baoquankhu1.vn
NanoViricides (NYSE:NNVC) Stock Price Down 4.8% – What’s Next? - Defense World
If You Invested $1,000 in Nanoviricides (NNVC) - Stock Titan
NNVC Stock Price, Quote & Chart | NANOVIRICIDES INC (NYSEARCA:NNVC) - ChartMill
EBITDA per share of NanoViricides, Inc. – FWB:NV3P - TradingView
Volume Recap: Can NanoViricides Inc grow without external funding2026 Momentum Check & Consistent Return Strategy Ideas - baoquankhu1.vn
NanoViricides Announces Closing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close - Beaver County Times
In Treating Measles Infection, NV-387 Showed Strong Antiviral Activity, and Significantly, Protected Lungs from Damage, Describes NanoViricides - The Register-Guard
NanoViricides, Inc. Has Filed its Quarterly ReportSubsequent Raise Has Fortified Fiscal Position - The Asheville Citizen Times
NanoViricides Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is Complete - ACCESS Newswire
NanoViricides Completes Manufacturing of NV-387 Oral Gummies, Prepares for Phase II Monkeypox Trial - citybuzz -
Aug Setups: Can NanoViricides Inc continue delivering strong returns2026 EndofMonth & Stepwise Trade Execution Plans - baoquankhu1.vn
Small cap wrap: NanoViricides, Millennial Potash, Gunnison Copper, Century Lithium… - Proactive Investors
NanoViricides completes manufacturing of NV-387 oral drug ahead of Phase II mpox trial - Yahoo! Finance Canada
Antiviral NV-387 heads to Phase II mpox trial with new gummy form - Stock Titan
Jobs Data: Can NanoViricides Inc continue delivering strong returnsMarket Volume Report & Community Verified Trade Signals - baoquankhu1.vn
Sell Signal: Is NanoViricides Inc subject to activist investor interest2025 Investor Takeaways & Low Risk Growth Stock Ideas - baoquankhu1.vn
NNVC Earnings History & Surprises | EPS & Revenue Results | NANOVIRICIDES INC (NYSEARCA:NNVC) - ChartMill
NanoViricides to Present at the PODD 2025 Conference in Boston on October 27 - The Asheville Citizen Times
getLinesFromResByArray error: size == 0 What is NanoViricides Inc.’s TAM (Total Addressable Market)Portfolio Gains Report & Growth Focused Entry Reports - mfd.ru
US Stocks Recap: Is NanoViricides Inc forming a breakout patternJuly 2025 WrapUp & Community Trade Idea Sharing - baoquankhu1.vn
Aug Fed Impact: Can NanoViricides Inc continue delivering strong returnsQuarterly Earnings Report & Long-Term Safe Investment Plans - baoquankhu1.vn
NanoViricides CEO discusses progress of broad-spectrum antiviral candidate NV-387ICYMI - Proactive financial news
Growth Value: Will NanoViricides Inc benefit from rate cutsJuly 2025 Price Swings & AI Forecasted Entry/Exit Points - baoquankhu1.vn
Small cap wrap: Aftermath Silver, M2i Global, NanoViricides, AtaiBeckley… - Proactive financial news
NanoViricides advances toward fully funded Phase II MPox trial in DRC - Proactive financial news
NanoViricides advances broad-spectrum antiviral NV-387 towards Phase II MPox study - Yahoo Finance
NanoViricides: Fiscal Q2 Earnings Snapshot - kare11.com
NanoViricides: Fiscal Second Quarter Earnings Overview - Bitget
Moving Averages: Is NanoViricides Inc exposed to political riskJuly 2025 Movers & Growth Focused Stock Reports - baoquankhu1.vn
Can NanoViricides Inc grow without external fundingJuly 2025 Review & Growth Focused Stock Reports - baoquankhu1.vn
Small cap wrap: BioVie, VivoPower, NanoViricides, Aftermath Silver... - Proactive financial news
NanoViricides seeks FDA orphan status for MPox drug - Yahoo Finance
MPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides - Bitget
New Mpox drug candidate NV-387 chases FDA orphan status - Stock Titan
NanoViricides Files for Orphan Drug Status as U.S. Measles Cases Surge (MRNA,QNCX) - Barchart.com
NanoViricides Comments on the Need for Broad-Spectrum Antivirals in Light of the Current Influenza WaveNV-387 is Effective Against H3N2 - Ventura County Star
Small cap wrap: Medicus Pharma, 1911 Gold, NanoViricides, Nextech3D.ai, NextSource Materials… - Proactive Investors
Measles Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides - USA Today
NanoViricides seeks orphan drug status with US FDA for measles treatment - Yahoo Finance
Measles cases surge as NanoViricides seeks orphan status for NV-387 - Stock Titan
NanoViricides President Dr. Diwan Interviewed by Mission Matters’ Adam Torres - USA Today
NanoViricides Inc Stock (NNVC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.04%
0.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):